A Drug That Could Regrow Missing Teeth Moves Into Phase II Trials

A Kyoto University spinout called Toregem BioPharma is advancing its experimental drug, TRG035, into Phase II clinical trials this summer — the first time the treatment will be given to patients who actually have the condition it is meant to address.

The Phase II trial will test the antibody in people with severe congenital hypodontia, defined as the absence of six or more permanent teeth.

To fund this stage of development,

the company raised approximately US$5.3 million to support Phase II clinical trials of TRG035 in Japan.

The drug works by interfering with a specific protein in the body.

TRG035 blocks USAG-1, a protein that suppresses tooth development, with the goal of activating dormant tooth buds and stimulating new tooth growth.

The approach is rooted in the concept that humans retain vestigial tooth buds capable of producing a third set of teeth, but that USAG-1 normally prevents these from developing.

Before this Phase II study,

Phase I trials in healthy adults with at least one missing tooth concluded without serious adverse events.

For now, the research is focused on a narrow patient group.

The drug is being developed first for severe congenital hypodontia, rather than adult acquired tooth loss, and remains investigational.

For pediatric patients with severe hypodontia, the clinical stakes are significant, because implants cannot usually be placed until jaw growth is complete, meaning children may be managed with removable dentures for years.

Broader applications remain a longer-term goal rather than a near-term promise.

While researchers ultimately hope the approach could be used for adult patients with acquired tooth loss, that remains a longer-term goal.

The research team has set a provisional target of having the medicine ready for general use by 2030, though TRG035 still needs Phase II efficacy data and further regulatory review before it could become available.

For patients curious about regenerative dentistry, this is a development worth watching — steadily, and with measured expectations.